Imperfect compliance evaluation of drug efficacy in clinical trials of the instrumental variables estimation.docVIP

 PAGE \* MERGEFORMAT 14 Imperfect compliance evaluation of drug efficacy in clinical trials of the instrumental variables estimation Abstract randomized controlled clinical trials of the intention to treat analysis always assume that subjects have a perfect compliance, again compared between the treatment group and control group differences in efficacy. However, in clinical trials is a common non-compliance, a subject’s compliance with the quality of test results is closely related to non-compliance or poor compliance led to ineffective treatment of the most common reasons for conducting evaluation of drug efficacy , also contributed to bias an important factor. This study consider conditions of imperfect compliance, using instrumental variables given drug efficacy evaluation method. Keywords: Clinical evaluation Abstract In randomied clinical trials, the intention to treat approach has long served as a standard methodological procedure, which just compare response distributions by assignment, ignoring information on compliance. In fact, however, non  compliance is common in many trials. Moreover, compliance is related to the quality of treatment evaluation. Many erroneous conclusion is usually attributed to non-compliance, and non  compliance can also lead to a bias on treatment effects evaluating. This paper presents an estimator of treatment effects by instrumental variables under non  compliance . Keywords: estimating treatment effects; randomized clinical trials; non  compliance; instrumental variable Adherence (compliance) refers to the implementation of living wills patients an objective response level. Clinical trials of new drugs is the human body (patients or healthy volunteers) conducted on the drug effects of a series of clinical experimental study to confirm or reveal the experimental drug efficacy and adverse reactions, the purpose is to determine the test drug efficacy and safety. So in new drug clinical